{"disease":{"id":"metastatic-nonsmall-cell-lung-cancer","name":"metastatic nonsmall cell lung cancer"},"drugs":{"marketed":[{"drug_id":"ipilimumab","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"yervoy","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06607393","title":"CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]","phase":"","overall_status":"COMPLETED","enrollment_count":851,"lead_sponsor_name":"Aetion, Inc.","has_results":false},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03512847","title":"Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Zealand University Hospital","has_results":false},{"nct_id":"NCT03044626","title":"Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03415126","title":"A Study of ASN007 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Asana BioSciences","has_results":false},{"nct_id":"NCT03825510","title":"Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Crozer-Keystone Health System","has_results":false},{"nct_id":"NCT06555263","title":"Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}